Sarcoma News The FDA has granted accelerated approval to Tazverik™ (tazemetostat tablets; Epizyme) for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Findings seen among patients <40 years with bone or soft tissue sarcomas, regardless of disease stage.
A “bionic” T cell that is armed with a bispecific antibody but lacks a chimeric antigen receptor showed cytotoxic activity in cancer cell lines.
A single-day, cGMP-compliant manufacturing process to make a cryopreserved drug product, if successful, could dramatically reduce patient wait times.
Uncontained uterine power morcellation tied to higher mortality in women with undetected uterine cancer.
An analysis of how functional outcomes are measured in patients with soft tissue sarcoma revealed the efficacy of salvage surgery, and a need to improve frequency of FO measurements.
Combination chemotherapy and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Investigators from the ANNOUNCE trial suggested potential explanations for why there were such different outcomes across 2 of its trials.
The FDA has granted Breakthrough Therapy designation to Pomalyst (pomalidomide; Celgene) for the treatment of patients with Kaposi sarcoma.
Lilly is working to establish an access program to provide Lartruvo to patients who wish to continue treatment.
Detection across tumor types supports the use of next-generation sequencing.
This study used comprehensive microarray analysis of serum to identify a panel of 7 miRNAs specific to sarcoma.
According to researchers, older age and black race were independent predictors of poor OS in women with stage I uterine leiomyosarcoma.
FDA issued a statement recommending against the use of olaratumab in new patients with sarcoma following the release of negative results from the phase 3 ANNOUNCE trial.
Results from a phase 1 study suggest that larotrectinib could be a new standard of care in TRK-fusion cancers.
Eight in 10 patients with DFSP saw a clinical benefit from treatment with imatinib.
Could sorafenib be the new standard of care for desmoid tumors?
mTOR inhibition is thought to enhance the efficacy of chemotherapy.
The outcomes of patients with ESTS did not improve as a result of induction ILP prior to surgical intervention.
The researchers conducted a retrospective cohort study of patients with advanced STS treated at a single institution over a 12 month period.
Load More
